CytoDyn (CYDY)
(Delayed Data from OTC)
$0.16 USD
0.00 (-2.68%)
Updated Sep 20, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
CytoDyn Inc. [CYDY]
Reports for Purchase
Showing records 41 - 60 ( 82 total )
Company: CytoDyn Inc.
Industry: Medical - Drugs
Initial Section of Rolling Biologics License Application Filed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Positive Preclinical Results in Triple Negative Breast Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
FDA Grants Rolling Review of Leronlimab Biologics License Application; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Preclinical Studies to Start in Eight Cancer Indications; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Positive Update on Dosing Upgrade Following FDA Meeting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Positive Clinical Results From Prostate Cancer Prognostic Test; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Triple Negative Breast Cancer Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
HIV Monotherapy Response Rate Reaches 92%; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
IND for Triple Negative Breast Cancer Filed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Prostate Cancer Prognostic Test to Enter Clinical Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Pivotal PRO 140 HIV Monotherapy Study May Start in 1H19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
PRO 140 to Be Developed for Triple Negative Breast Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Positive Preclinical Results in Colon Cancer; IND Filing Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
PRO 140 Higher Dose Improves Maintenance Response; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
PRO 140 Delivers Impressive 25-Week Efficacy in Pivotal HIV Combo Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Strategic Expansion Into Oncology With Potential Acquisition of ProstaGene; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
GvHD Phase 2 Protocol Amended; Faster Enrollment Expected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
Ibalizumab Approval Paves Way for Humanized mAb as HIV Treatment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
PRO 140 Meets Primary Endpoint in Pivotal HIV Combo Trial; Reiterate Buy and Raising Target to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CytoDyn Inc.
Industry: Medical - Drugs
HIV Pivotal Efficacy Readout Possible This Quarter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R